 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 February 1993 | Volume 118 Issue 4 | Pages 268-272
Objective: To determine whether oral acyclovir reduces the incidence of recurrent herpes labialis in otherwise healthy patients with proven frequently recurrent disease.
Design: Randomized, double-blind, placebo-controlled, crossover trial.
Setting: Outpatient facility of the Clinical Center, National Institutes of Health, Bethesda, Maryland.
Patients: Fifty-six otherwise healthy adults who reported frequently recurrent herpes labialis (
Interventions: Twenty-two patients were randomized to receive either acyclovir, 400 mg twice daily, or matched placebo for 4 months. After the first treatment period, patients were given the alternate treatment for another 4 months and were then taken off study medication to observe the first post-treatment recurrence. Recurrent outbreaks were determined by examination and by viral culture.
Results: Twenty patients completed blind treatment with both acyclovir and placebo. The median time to first clinically documented recurrence was 46 days for placebo courses and 118 days for acyclovir courses (P = 0.05). The mean number of recurrences per 4-month treatment period was 1.80 episodes per patient during placebo treatment and 0.85 episodes per patient during acyclovir treatment (P = 0.009). The mean number of virologically confirmed recurrences per patient was 1.40 with placebo therapy compared with 0.40 with acyclovir (P = 0.003).
Conclusions: Oral acyclovir, 400 mg twice daily, is effective in suppressing herpes labialis in immunocompetent adults confirmed to have frequently recurrent infection. Treatment with acyclovir in this study resulted in a 53% reduction in the number of clinical recurrences and a 71% reduction in virus culture-positive recurrences compared with placebo therapy.
Author and Article Information
From the National Institute of Dental Research and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
ARTICLE
Oral Acyclovir To Suppress Frequently Recurrent Herpes Labialis: A Double-Blind, Placebo-Controlled Trial
6 episodes/y) were enrolled into the study. During a 4-month observation period, 22 patients had herpes labialis two or more times and were eligible for study treatment.
Request for Reprints: James F. Rooney, MD, Laboratory of Oral Medicine, National Institute of Dental Research, National Institutes of Health, Building 30, Room 121, Bethesda, MD 20892.
Acknowledgments: The authors thank George Grimes, Jr., PD, Sanjay Jagannath, BS, L. Gray Davis, PhD, Gloria Boone, BS, MBA, and Stephen Banks, PhD, for assistance in study design and execution and Eloise Mange for editorial assistance.
Grant Support: In part by Burroughs Wellcome Company, Research Triangle Park, North Carolina.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Opstelten, A. K. Neven, and J. Eekhof Treatment and prevention of herpes labialis Can Fam Physician, December 1, 2008; 54(12): 1683 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cernik, K. Gallina, and R. T. Brodell The Treatment of Herpes Simplex Infections: An Evidence-Based Review Arch Intern Med, June 9, 2008; 168(11): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. MILLER, L. L. CUNNINGHAM, J. E. LINDROTH, and S. A. AVDIUSHKO The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures J Am Dent Assoc, September 1, 2004; 135(9): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A Jensen, J. D Hoehns, and C. L Squires Oral Antivirals for the Acute Treatment of Recurrent Herpes Labialis Ann. Pharmacother., April 1, 2004; 38(4): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Spruance, R. Nett, T. Marbury, R. Wolff, J. Johnson, and T. Spaulding Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2238 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Kaufman Can We Prevent Recurrences of Herpes Infections without Antiviral Drugs? The Weisenfeld Lecture Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1325 - 1329. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vander Straten, D. Carrasco, P. Lee, and S. K. Tyring A Review of Antiviral Therapy for Herpes Labialis Arch Dermatol, September 1, 2001; 137(9): 1232 - 1235. [Full Text] [PDF]
|
|
|
|
|
|
M. Lipsitch, T. H. Bacon, J. J. Leary, R. Antia, and B. R. Levin Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2824 - 2835. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. R. Wilhelmus, R. W. Beck, P. S. Moke, C. R. Dawson, B. A. Barron, D. B. Jones, H. E. Kaufman, N. Kurinij, R. D. Stulting, J. Sugar, et al. Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease N. Engl. J. Med., July 30, 1998; 339(5): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Choudhury, D. S. Hodes, V. B. Peters, and E. J. Bottone Cutaneous Herpes Simplex Virus Infection in a Child With Acquired Immunodeficiency Syndrome Clinical Pediatrics, November 1, 1994; 33(11): 698 - 700. [Abstract] [PDF]
|
|
|
|
 |
|
 Acyclovir Suppresses Recurrent Labial Herpes Journal Watch Dermatology, April 1, 1993; 1993(401): 12 - 12. [Full Text]
|
|
|
|
 |
|
 ACYCLOVIR SUPPRESSES RECURRENT LABIAL HERPES Journal Watch (General), February 23, 1993; 1993(223): 1 - 1. [Full Text]
|
|
